Literature DB >> 24460899

Melatonin from cerebrospinal fluid but not from blood reaches sheep cerebral tissues under physiological conditions.

C Legros1, D Chesneau, J A Boutin, C Barc, B Malpaux.   

Abstract

The pineal gland secretes melatonin (MLT) that circulates in the blood and cerebrospinal fluid (CSF). We provide data to support the hypothesis that, in sheep and possibly in humans, only the CSF MLT, and not the blood MLT, can provide most of MLT to the cerebral tissue in high concentrations, particularly in the periventricular area. The MLT content of sheep brain, our chosen animal model, was found in significant concentration gradients oriented from the ventricle (close to the CSF) to the cerebral tissue, with concentrations varying by a factor of 1-125. The highest concentrations were observed close to the ventricle wall, whereas the lowest concentrations were furthest from the ventricles (407.0 ± 71.5 pg/ml compared to 84.7 ± 5.2 pg/ml around the third ventricle). This concentration gradient was measured in brain tissue collected at mid-day and at the end of the night. Nocturnal concentrations were higher than daytime concentrations, reflecting the diurnal variation in the pineal gland. The concentration gradient was not detected when MLT was delivered to the brain via the bloodstream. The diffusion of MLT to cerebral tissues via CSF was supported by in vivo scintigraphy and autoradiography. 2-[(123)I]-MLT infused into the CSF quickly and efficiently diffused into the brain tissues, whereas [(123)I]-iodine (control) was mostly washed away by the CSF flow and [(123)I]-bovine serum albumin remained mostly in the CSF. Taken together, these data support a critical role of CSF in providing the brain with MLT.
© 2014 British Society for Neuroendocrinology.

Entities:  

Keywords:  blood flow; brain; cerebrospinal fluid; diffusion; in vivo scintigraphy; melatonin; sheep; transport; ventricles

Mesh:

Substances:

Year:  2014        PMID: 24460899     DOI: 10.1111/jne.12134

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  21 in total

Review 1.  Update on melatonin receptors: IUPHAR Review 20.

Authors:  Ralf Jockers; Philippe Delagrange; Margarita L Dubocovich; Regina P Markus; Nicolas Renault; Gianluca Tosini; Erika Cecon; Darius P Zlotos
Journal:  Br J Pharmacol       Date:  2016-08-08       Impact factor: 8.739

2.  Why Are We Still Cloning Melatonin Receptors? A Commentary.

Authors:  Célia Gautier; Isabelle Theret; Giulia Lizzo; Gilles Ferry; Sophie-Pénélope Guénin; Jean A Boutin
Journal:  Methods Mol Biol       Date:  2022

3.  Detection of Melatonin in Tissue Samples.

Authors:  Céline Legros; Jean A Boutin
Journal:  Methods Mol Biol       Date:  2022

Review 4.  Immune-pineal axis - acute inflammatory responses coordinate melatonin synthesis by pinealocytes and phagocytes.

Authors:  Regina P Markus; Pedro A Fernandes; Gabriela S Kinker; Sanseray da Silveira Cruz-Machado; Marina Marçola
Journal:  Br J Pharmacol       Date:  2017-12-15       Impact factor: 8.739

Review 5.  Melatonin in type 2 diabetes mellitus and obesity.

Authors:  Angeliki Karamitri; Ralf Jockers
Journal:  Nat Rev Endocrinol       Date:  2019-02       Impact factor: 43.330

Review 6.  Melatonin Therapy in Patients with Alzheimer's Disease.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Luis I Brusco
Journal:  Antioxidants (Basel)       Date:  2014-04-10

7.  Preoperative CSF Melatonin Concentrations and the Occurrence of Delirium in Older Hip Fracture Patients: A Preliminary Study.

Authors:  Rikie M Scholtens; Sophia E J A de Rooij; Annelies E Vellekoop; Bart C Vrouenraets; Barbara C van Munster
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

Review 8.  Mechanisms of Melatonin in Alleviating Alzheimer's Disease.

Authors:  Mayuri Shukla; Piyarat Govitrapong; Parichart Boontem; Russel J Reiter; Jutamaad Satayavivad
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 9.  Melatonin as a potential inhibitory agent in head and neck cancer.

Authors:  Chia-Ming Yeh; Shih-Chi Su; Chiao-Wen Lin; Wei-En Yang; Ming-Hsien Chien; Russel J Reiter; Shun-Fa Yang
Journal:  Oncotarget       Date:  2017-08-09

Review 10.  Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.

Authors:  Josiel Mileno Mack; Marissa Giovanna Schamne; Tuane Bazanella Sampaio; Renata Aparecida Nedel Pértile; Pedro Augusto Carlos Magno Fernandes; Regina P Markus; Rui Daniel Prediger
Journal:  Oxid Med Cell Longev       Date:  2016-10-18       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.